Cereno Scientific terminates agreement with liquidity provider
Cereno Scientific announced today that the agreement with Mangold Fondkommission to act as liquidity provider for the company’s share has been terminated. The share has a good spread and a liquidity provider is therefore no longer needed. The assignment will end on December 29, 2020, without a new liquidity provider agreement replacing the previous commitment.For further information, please contact:Daniel Brodén, CFOTel: +46 768 66 77 87Email: info@cerenoscientific.comwww.cerenoscientific.com About Cereno Scientific ABCereno Scientific is a leading clinical stage biotech